IL-17 Blockade in Psoriasis

IL-17 Blockade in Psoriasis

IL-17A both directly induces and synergizes with other cytokines to promote autoimmune tissue inflammation. Secukinumab and ixekizumab are monoclonal antibodies (mAb) that inhibit interleukin-17A. These two agents were recently approved for treatment of psoriasis, and secukinumab is also approved for treatment of two spondyloarthropathies, psoriatic arthritis and ankylosing spondylitis.

Therapeutic implications of IL-17A blockade in psoriasis.

The discovery of T helper type 17 lymphocytes in 2005 represented an important advance in understanding the immunopathogenesis of immunologically mediated inflammatory diseases, by identifying an important source of cytokine IL-17A, whose role in autoimmune diseases has been identified in experimental models. Over 15 years ago, the role of IL-17A in the pathogenesis of psoriasis and its proinfl...

Role of IL-17 in psoriasis and psoriatic arthritis.

The role of T cell subpopulations in human disease is in a transition phase due to continuous discovery of new subsets of T cell, one of which is Th17, characterized by the production of signature cytokine IL-17. In the last couple of years, many articles are coming out on the role of Th17 and its signature cytokine IL-17 in different autoimmune diseases like rheumatoid arthritis, psoriasis, ps...

Blockade of Phosphatidylinositol 3-Kinase (PI3K)d or PI3Kg Reduces IL-17 and Ameliorates Imiquimod-Induced Psoriasis-like Dermatitis

Blockade of phosphatidylinositol 3-kinase PI3Kδ or PI3Kγ reduces IL-17 and ameliorates imiquimod-induced psoriasis-like dermatitis.

Psoriasis is a chronic inflammatory skin disease triggered by interplay between immune mediators from both innate and adaptive immune systems and skin tissue, in which the IL-23/IL-17 axis is critical. PI3Kδ and PI3Kγ play important roles in various immune cell functions. We found that mice lacking functional PI3Kδ or PI3Kγ are largely protected from imiquimod (IMQ)-induced psoriasis-like derma...